scholarly journals Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial

2017 ◽  
Vol 19 (6) ◽  
pp. 477-486 ◽  
Author(s):  
EM Tunbridge ◽  
MJ Attenburrow ◽  
A Gardiner ◽  
JM Rendell ◽  
C Hinds ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Folic Acid ◽  
Bipolar Depression ◽  
Genetic Predictors

The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial

Nutrition ◽  
2017 ◽  
Vol 38 ◽  
pp. 74-79 ◽  
Author(s):  
Gholamreza Askari ◽  
Morteza Nasiri ◽  
Hassan Mozaffari-Khosravi ◽  
Masod Rezaie ◽  
Mahdieh Bagheri-Bidakhavidi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Folic Acid ◽  
Controlled Clinical Trial ◽  
Double Blind

Relationship between placebo response rate and clinical trial outcome in bipolar depression

2016 ◽  
Vol 74 ◽  
pp. 38-44 ◽  
Author(s):  
Nadia Iovieno ◽  
Andrew A. Nierenberg ◽  
Susannah R. Parkin ◽  
Daniel Ju Hyung Kim ◽  
Rosemary S.W. Walker ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Response Rate ◽  
Bipolar Depression ◽  
Placebo Response ◽  
Placebo Response Rate ◽  
Trial Outcome ◽  
Clinical Trial Outcome

The treatment of bipolar disorder in children and adolescents

2017 ◽  
Author(s):  
Philip Hazell
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Young People ◽  
Relapse Prevention ◽  
Bipolar Depression ◽  
Mood Stabilizer ◽  
Acute Mania ◽  
Clinical Trial Evidence ◽  
Second Generation Antipsychotic ◽  
Trial Evidence

The presentation of bipolar disorder in young people can be different from that of adults; therefore, the approach to treatment differs slightly. Treatment is described for early intervention, acute mania, bipolar depression, relapse prevention, and refractory bipolar disorder. A strong therapeutic alliance with the patient and engagement and involvement of the patient’s family is critical to successful intervention. The evidence informing treatment is limited, but there is emerging research focused on the management of acute mania favouring monotherapy with a second-generation antipsychotic (SGA) over a mood stabilizer. Preliminary data favour a combination of an SGA and antidepressant over monotherapy with an SGA for the treatment of bipolar depression. Guidelines endorse electroconvulsive therapy for refractory mania and bipolar depression but there is no clinical trial evidence to support this practice. The development of algorithms to guide the management of all phases of bipolar disorder is a work in progress.

scholarly journals Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial

2019 ◽  
Vol 26 (3-4) ◽  
pp. 50-54
Author(s):  
Uma A. Bhosale ◽  
Radha Yegnanarayan ◽  
Akhil Agrawal ◽  
Ashwini Patil
Keyword(s):  
Risk Factors ◽  
Clinical Trial ◽  
Folic Acid ◽  
Antiepileptic Drugs ◽  
Chronic Medical Condition ◽  
Cvd Risk Factors ◽  
Cvd Risk ◽  
Study Results ◽  
Epileptic Patients

Background: Epilepsy is a chronic medical condition that requires long-term therapy with antiepileptic drugs (AEDs). However, long-term employment of AEDs may lead to the onset of hyperhomocysteinemia, which has been found to modulate imperative metabolic mechanisms and induce cardiovascular disorders (CVDs). Therefore, adolescent population that have been diagnosed with epilepsy and utilize AEDs are among the most vulnerable, exhibiting higher risks of developing CVDs. Purpose: The present study was designed to explore the effects of folic acid (FA) supplementation on AED-induced hyperhomocysteinemia and CVD risk factors in adolescent epileptics. Methods: The randomized clinical trial included adolescent epileptics (i.e., 10–19 years of age) of either sex, on antiepileptic therapy for > 6 months with high homocysteine levels (i.e., >10.9 µmol/L). At the time of enrolment, their baseline BP, lipid and homocysteine levels were recorded. Participants were randomly assigned to either treatment or placebo groups and received the respective treatments. At the end of the first month, BP, lipid and homocysteine levels were recorded and compared to determine the effect of FA on these parameters. Results and conclusion: A significant fall in homocysteine levels was observed with FA supplementation ( P < 0.05). However, this fall was significantly high in valproic acid treated epileptic patients. In addition, we observed an improvement in high-density lipoprotein levels, a risk factor for CVDs, but the change was statistically insignificant ( P > 0.05). The study results suggest that FA supplementation in epileptic patients receiving AED therapy may minimize AED-induced hyperhomocysteinemia and other CVD risk factors.

O28. Effect of folic acid supplementation in pregnancy on preeclampsia – Folic Acid Clinical Trial (FACT)

2015 ◽  
Vol 5 (3) ◽  
pp. 219-220
Author(s):  
Shi Wu Wen ◽  
Ruth Rennicks-White ◽  
Josee Champagne ◽  
Natalie Rybak ◽  
Laura Gaudet ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Folic Acid ◽  
Folic Acid Supplementation ◽  
Acid Supplementation ◽  
In Pregnancy

scholarly journals Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial

BMJ Open ◽  
2012 ◽  
Vol 2 (1) ◽  
pp. e000643 ◽  
Author(s):  
Jonathan Savitz ◽  
Sheldon Preskorn ◽  
T Kent Teague ◽  
Douglas Drevets ◽  
William Yates ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bipolar Depression ◽  
Proof Of Concept ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document